U.S. markets open in 4 minutes

CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.61-0.38 (-6.34%)
At close: 04:00PM EST
5.63 +0.02 (+0.36%)
Pre-Market: 09:25AM EST

CTI BioPharma Corp.

3101 Western Avenue
Suite 800
Seattle, WA 98121
United States
206 282 7100

Full Time Employees121

Key Executives

NameTitlePayExercisedYear Born
Dr. Adam R. Craig M.B.A., M.D., Ph.D.Pres, CEO, Interim Chief Medical Officer & Director1.02MN/A1966
Mr. David H. KirskeExec. VP, CFO & Sec.542.34kN/A1954
Mr. Ed BellSr. Director of Investor RelationsN/AN/AN/A
Mr. James K. FongExec. VP & Chief Commercial OfficerN/AN/A1962
Mr. Bruce K. Bennett Jr.Sr. VP Global Pharmaceutical OperationsN/AN/A1952
Mr. John P. VolponeExec. VP & Chief of StaffN/AN/AN/A
Dr. Jennifer A. SmithSr. VP of BiometricsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Corporate Governance

CTI BioPharma Corp.’s ISS Governance QualityScore as of December 1, 2022 is 2. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.